Onderneming Antibe Therapeutics Inc Toronto S.E.
Aandelen
ATE
CA0370251039
Biotechnologie & Medisch Onderzoek
Vakgebied
Managers
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Alain Wilson
DFI | Director of Finance/CFO | - | 01-12-15 |
Chief Tech/Sci/R&D Officer | - | - | |
Ana Stegic
CTO | Chief Tech/Sci/R&D Officer | - | - |
Scott Curtis
COO | Chief Operating Officer | - | 01-01-16 |
Joseph Stauffer
CTO | Chief Tech/Sci/R&D Officer | 58 | 06-05-20 |
Investor Relations Contact | - | - | |
David Vaughan
PRN | Corporate Officer/Principal | 74 | 01-11-12 |
Corporate Officer/Principal | - | - |
Besturend
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Director/Board Member | 50 | 24-11-20 | |
Amal Khouri
BRD | Director/Board Member | - | 19-03-18 |
Aandelenklasse
Stemming | Aantal | Vrij verhandelbaar | Bedrijfseigen aandelen | Drijvend Totaal | |
---|---|---|---|---|---|
Aandeel A | 1 | 53 009 362 | 48 481 043 ( 91,46 %) | 0 | 91,46 % |
Bedrijfsgegevens
Antibe Therapeutics, Inc.
15 Prince Arthur Avenue
M5R 1B2, Toronto
+416-922-3460
http://www.antibethera.comSector
Vaira. 1 jan. | Kapi. | |
---|---|---|
+8,63% | 115 mld. | |
+13,17% | 107 mld. | |
-12,76% | 22,31 mld. | |
-3,99% | 21,6 mld. | |
-7,19% | 18,23 mld. | |
-39,93% | 17,62 mld. | |
+6,67% | 14,26 mld. | |
+33,90% | 12,37 mld. | |
-28,60% | 8,28 mld. |